The First Crispr Treatment Is Making Its Way to Patients
It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
Pharmabiz2d
Arch Biopartners doses first patient in Canada for phase II trial of LSALT peptide to treat cardiac surgery associated acute kidney injury
Arch Biopartners doses first patient in Canada for phase II trial of LSALT peptide to treat cardiac surgery associated acute kidney injury: Toronto Wednesday, November 13, 2024, 1 ...
clinicaltrialsarena2d
Arch Biopartners doses first subject in trial of acute kidney injury treatment
Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of LSALT peptide (Metablok) for acute ...